Table 4. Variation in sodium and potassium levels as a function of best objective response to sorafenib.
| No. patients | Percentage variation after 15 days | ||
|---|---|---|---|
| Median value (IQR) | Median value (SD) | ||
| Sodium | |||
| Overall | 61 | 0 (−3 to 12.3) | 1.6 (2.8) |
| DCR | 19 | 3 (0 to 8.2) | 3.3 (2.5) |
| PD | 32 | 0 (−3 to 5.1) | 0.25 (1.8) |
| p (between DCR and PD) | <0.00011 | ||
| Potassium | |||
| Overall | 61 | −2 (−41 to 38.13) | −5.7 (13.4) |
| DCR | 19 | −16 (−37 to 38.20) | −11.1 (16.0) |
| PD | 32 | 0.50 (−41 to 14. 7) | −1.06 (10.2) |
| p (between DCR and PD) | 0.00071 | ||
IQR, interquartile range; DCR, disease control rate; PD, progressive disease; SD, standard deviation
1
Wilcoxon median test